SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-044810
Filing Date
2024-11-12
Accepted
2024-11-12 16:50:35
Documents
59
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1674138
2 ex31-1.htm EX-31.1 11171
3 ex31-2.htm EX-31.2 11349
4 ex32-1.htm EX-32.1 4731
5 ex32-2.htm EX-32.2 4770
  Complete submission text file 0001493152-24-044810.txt   7557583

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE lixt-20240930.xsd EX-101.SCH 47949
7 XBRL CALCULATION FILE lixt-20240930_cal.xml EX-101.CAL 33537
8 XBRL DEFINITION FILE lixt-20240930_def.xml EX-101.DEF 244395
9 XBRL LABEL FILE lixt-20240930_lab.xml EX-101.LAB 419764
10 XBRL PRESENTATION FILE lixt-20240930_pre.xml EX-101.PRE 330720
61 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1343647
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

IRS No.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39717 | Film No.: 241449377
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)